<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">34414532</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>10</Month>
        <Day>13</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>02</Month>
        <Day>18</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1573-7217</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>189</Volume>
            <Issue>3</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Oct</Month>
            </PubDate>
          </JournalIssue>
          <Title>Breast cancer research and treatment</Title>
          <ISOAbbreviation>Breast Cancer Res Treat</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded population.</ArticleTitle>
        <Pagination>
          <StartPage>689</StartPage>
          <EndPage>699</EndPage>
          <MedlinePgn>689-699</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1007/s10549-021-06334-0</ELocationID>
        <Abstract>
          <AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">CompLEEment-1 is a phase 3b trial in an expanded patient population with hormone receptor-positive (HR +), human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancer (ABC), the largest current trial of cyclin-dependent kinase 4 and 6 inhibitors in ABC.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">Patients treated with ≤ 1 line of prior chemotherapy and no prior endocrine therapy for ABC received ribociclib 600 mg/day (3-weeks-on/1-week-off) plus letrozole 2.5 mg/day and additionally monthly goserelin/leuprolide in men and pre-/perimenopausal women. Eligibility criteria allowed inclusion of patients with stable CNS metastases and an Eastern Cooperative Oncology Group performance status of 2. Primary objectives were safety and tolerability, and secondary objectives were efficacy and quality of life (QoL).</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">Overall, 3,246 patients were evaluated (median follow-up 25.4 months). Rates of all-grade and grade ≥ 3 treatment-related adverse events (AEs) were 95.2% and 67.5%, respectively. Treatment-related discontinuations due to all grade and grade ≥ 3 AEs occurred in 12.9% and 7.3% of patients, respectively. Rates of all-grade AEs of special interest (AESI) were as follows: neutropenia (74.5%), increased alanine aminotransferase (16.2%), increased aspartate aminotransferase (14.1%), and QTcF prolongation (6.7%); corresponding values for grade ≥ 3 AESI were 57.2%, 7.7%, 5.7%, and 1.0%, respectively. Median time to progression was 27.1 months (95% confidence interval, 25.7 to not reached). Patient QoL was maintained during treatment.</AbstractText>
          <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Safety and efficacy data in this expanded population were consistent with the MONALEESA-2 and MONALEESA-7 trials and support the use of ribociclib plus letrozole in the first-line setting for patients with HR + , HER2- ABC.</AbstractText>
          <AbstractText Label="TRIAL REGISTRATION" NlmCategory="BACKGROUND">linicalTrials.gov NCT02941926.</AbstractText>
          <CopyrightInformation>© 2021. The Author(s).</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>De Laurentiis</LastName>
            <ForeName>Michelino</ForeName>
            <Initials>M</Initials>
            <Identifier Source="ORCID">0000-0001-9009-1572</Identifier>
            <AffiliationInfo>
              <Affiliation>Division of Breast Medical Oncology, Department of Breast and Thoracic Oncology Director, Istituto Nazionale Tumori IRCCS "Fondazione Pascale", Napoli, Italy. m.delaurentiis@istitutotumori.na.it.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Borstnar</LastName>
            <ForeName>Simona</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Oncology Ljubljana, Ljubljana, Slovenia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Campone</LastName>
            <ForeName>Mario</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Western Cancer Institute, Nantes, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Warner</LastName>
            <ForeName>Ellen</ForeName>
            <Initials>E</Initials>
            <AffiliationInfo>
              <Affiliation>Sunnybrook Health Sciences Centre, Toronto, ON, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bofill</LastName>
            <ForeName>Javier Salvador</ForeName>
            <Initials>JS</Initials>
            <AffiliationInfo>
              <Affiliation>Virgen del Rocío University Hospital, Biomedicine Institute, Seville, Spain.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Jacot</LastName>
            <ForeName>William</ForeName>
            <Initials>W</Initials>
            <AffiliationInfo>
              <Affiliation>Montpellier Cancer Institute, Montpellier, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Dent</LastName>
            <ForeName>Susan</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>The Ottawa Hospital Cancer Centre, Ottawa, ON, Canada.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Duke Cancer Institute, Duke University School of Medicine, Durham, NC, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Martin</LastName>
            <ForeName>Miguel</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Gregorio Marañón General University Hospital, GEICAM, Universidad Complutense, CIBERONC, Madrid, Spain.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ring</LastName>
            <ForeName>Alistair</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Royal Marsden Hospital NHS Foundation Trust, Sutton, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cottu</LastName>
            <ForeName>Paul</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Curie Institute, Paris, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lu</LastName>
            <ForeName>Janice</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>USC Norris Comprehensive Cancer Center, Los Angeles, CA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ciruelos</LastName>
            <ForeName>Eva</ForeName>
            <Initials>E</Initials>
            <AffiliationInfo>
              <Affiliation>University Hospital 12 de Octubre, Clara Campal Comprehensive Cancer Center (HM CIOCC), Madrid, Spain.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Azim</LastName>
            <ForeName>Hamdy A</ForeName>
            <Initials>HA</Initials>
            <AffiliationInfo>
              <Affiliation>Faculty of Medicine, Cairo University, Cairo, Egypt.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chatterjee</LastName>
            <ForeName>Sanjoy</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Tata Medical Center, Kolkata, India.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhou</LastName>
            <ForeName>Katie</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wu</LastName>
            <ForeName>Jiwen</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Menon-Singh</LastName>
            <ForeName>Lakshmi</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zamagni</LastName>
            <ForeName>Claudio</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Azienda Ospedaliero-Universitaria Di Bologna, Bologna, Italia.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <DataBankList CompleteYN="Y">
          <DataBank>
            <DataBankName>ClinicalTrials.gov</DataBankName>
            <AccessionNumberList>
              <AccessionNumber>NCT02941926</AccessionNumber>
            </AccessionNumberList>
          </DataBank>
        </DataBankList>
        <PublicationTypeList>
          <PublicationType UI="D017428">Clinical Trial, Phase III</PublicationType>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>08</Month>
          <Day>19</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Breast Cancer Res Treat</MedlineTA>
        <NlmUniqueID>8111104</NlmUniqueID>
        <ISSNLinking>0167-6806</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000631">Aminopyridines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011687">Purines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011960">Receptors, Estrogen</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011980">Receptors, Progesterone</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>7LKK855W8I</RegistryNumber>
          <NameOfSubstance UI="D000077289">Letrozole</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.10.1</RegistryNumber>
          <NameOfSubstance UI="D018719">Receptor, ErbB-2</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>TK8ERE8P56</RegistryNumber>
          <NameOfSubstance UI="C000589651">ribociclib</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <CommentsCorrectionsList>
        <CommentsCorrections RefType="ErratumIn">
          <RefSource>Breast Cancer Res Treat. 2021 Oct 8;:</RefSource>
          <PMID Version="1">34625861</PMID>
        </CommentsCorrections>
      </CommentsCorrectionsList>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000631" MajorTopicYN="N">Aminopyridines</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000971" MajorTopicYN="N">Antineoplastic Combined Chemotherapy Protocols</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001943" MajorTopicYN="Y">Breast Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000077289" MajorTopicYN="N">Letrozole</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011687" MajorTopicYN="N">Purines</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011788" MajorTopicYN="Y">Quality of Life</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018719" MajorTopicYN="N">Receptor, ErbB-2</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011960" MajorTopicYN="N">Receptors, Estrogen</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011980" MajorTopicYN="N">Receptors, Progesterone</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Advanced breast cancer</Keyword>
        <Keyword MajorTopicYN="N">CDK4/6 inhibitor</Keyword>
        <Keyword MajorTopicYN="N">Endocrine therapy</Keyword>
        <Keyword MajorTopicYN="N">Ribociclib</Keyword>
      </KeywordList>
      <CoiStatement>Michelino De Laurentiis has received honoraria for consulting or advisory roles from Amgen, AstraZeneca, Celgene, Eisai, Lilly, MSD, Novartis, Pfizer, Pierre Fabre, and Roche; Honoraria: Amgen, AstraZeneca, Celgene, Eisai, Lilly, MSD, Novartis, Pfizer, Pierre Fabre, and Roche; honoraria for participation in speakers’ bureau from Novartis; research funding from Bristol-Myers Squibb, Daiichi Sankyo, Lilly, Novartis, MacroGenics, MSD, Pfizer, Puma Biotechnology, and Roche. Simona Borstnar has received honoraria for consulting or advisory roles from Amgen, AstraZeneca, Lilly, Novartis, Pfizer, and Roche; honoraria for participation in speakers’ bureaux from Amgen, Lilly, Krka, Novartis, Pfizer, and Roche. Mario Campone has received honoraria for consulting or advisory roles from AstraZeneca, Novartis, AbbVie, Sanofi, Lilly, Pfizer, Sandoz, Servier, Accord, and Pierre Fabre; honoraria from Novartis and Lilly; honoraria for participation in speakers’ bureaux from Novartis and Lilly; reimbursement for travel, accommodations, and expenses from Pfizer, Roche, and AstraZeneca. Ellen Warner has received reimbursement for travel, accommodations, or expenses from Novartis. Javier Salvador Bofill has received honoraria for consulting or advisory roles from Roche, Novartis, Pfizer, and MSD; honoraria for participation in speakers’ bureaux from Novartis and Roche; honoraria from Novartis, Pfizer, and Roche; reimbursement for travel, accommodations, or expenses from Roche, Novartis, and Pfizer. William Jacot has received honoraria for consulting or advisory roles from AstraZeneca, Eisai, Lilly France, MSD, Novartis, Pfizer, and Roche; research funding from AstraZeneca; reimbursement for travel, accommodations, or expenses from AstraZeneca, Chugai Pharma, Eisai, GlaxoSmithKline, and Lilly France. Susan Dent has received honoraria for consulting or advisory roles from Novartis, Pfizer, and Roche; honoraria from Eli Lilly, Novartis, and Roche; research funding from Hoffman La-Roche, Novartis, and Pfizer; reimbursement for travel, accommodations, or expenses from AstraZeneca. Miguel Martin has received honoraria for consulting or advisory roles from Amgen, AstraZeneca, Eli Lilly, Novartis, Pfizer, PharmaMar, Puma Biotechnology, Roche/Genentech, and Taiho Oncology; honoraria for participation in speakers’ bureaux from AstraZeneca, Amgen, Roche/Genentech, Novartis, and Pfizer; research funding from Roche and Novartis. Alistair Ring has received honoraria for consulting or advisory roles from Pfizer and Roche; honoraria from AstraZeneca, Lilly, Novartis, Pfizer, and Roche; research funding from AstraZeneca. Paul Cottu has received honoraria for consulting or advisory roles from Novartis and Pfizer; research funding from AstraZeneca, Genentech/Roche, Novartis, Pierre Fabre, and Pfizer; reimbursement for travel, accommodations, or expenses from AstraZeneca, NanoString Technologies, Novartis, Pfizer, and Roche. Janice Lu has received honoraria for consulting or advisory roles from Pfizer, Novartis, and Puma. Eva Ciruelos has received honoraria for consulting or advisory roles from Pfizer, Novartis, Lilly, and Roche; honoraria from Pfizer, Novartis, Lilly, and Roche; honoraria for participation in speakers’ bureaux from Pfizer, Novartis, Lilly, and Roche; reimbursement for travel, accommodations, or expenses from Pfizer and Roche. Hamdy A. Azim has received honoraria for consulting or advisory roles from ASZ, Bristol-Myers Squibb, Janssen, MSD, Novartis, Pfizer, Amgen, Lilly, and Roche; employment by Innate France (immediate family member); honoraria from Amgen, ASZ, Bristol-Myers Squibb, MSD, Novartis, Pfizer, and Roche; research funding from Pfizer. Sanjoy Chatterjee has received honoraria for consulting or advisory roles from Tata Medical Center. Katie Zhou is employed by Novartis. Jiwen Wu is employed by Novartis. Lakshmi Menon-Singh is employed by Novartis. Claudio Zamagni has received honoraria for consulting or advisory roles from AstraZeneca, Eisai, Novartis, Pfizer, PharmaMar, Pierre Fabre, and Roche; research funding from AbbVie, Array BioPharma, AstraZeneca, Celgene, Medivation, Morphotek, Novartis, Pfizer, Roche, and Roche/Genentech; reimbursement for travel, accommodations, or expenses from Celgene, Novartis, Pierre Fabre, and Roche.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2020</Year>
          <Month>12</Month>
          <Day>7</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>7</Month>
          <Day>14</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>8</Month>
          <Day>21</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>14</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>8</Month>
          <Day>20</Day>
          <Hour>7</Hour>
          <Minute>17</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34414532</ArticleId>
        <ArticleId IdType="pmc">PMC8505291</ArticleId>
        <ArticleId IdType="doi">10.1007/s10549-021-06334-0</ArticleId>
        <ArticleId IdType="pii">10.1007/s10549-021-06334-0</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Anderson WF, Chatterjee N, Ershler WB, Brawley OW. Estrogen receptor breast cancer phenotypes in the Surveillance, Epidemiology, and End Results database. Breast Cancer Res Treat. 2002;76:27–36. doi: 10.1023/A:1020299707510.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1023/A:1020299707510</ArticleId>
            <ArticleId IdType="pubmed">12408373</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Osborne CK, Schiff R. Mechanisms of endocrine resistance in breast cancer. Annu Rev Med. 2011;62:233–247. doi: 10.1146/annurev-med-070909-182917.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1146/annurev-med-070909-182917</ArticleId>
            <ArticleId IdType="pmc">PMC3656649</ArticleId>
            <ArticleId IdType="pubmed">20887199</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Setiawan VW, Monroe KR, Wilkens LR, et al.  Breast cancer risk factors defined by estrogen and progesterone receptor status: The multiethnic cohort study. Am J Epidemiol. 2009;169:1251–1259. doi: 10.1093/aje/kwp036.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/aje/kwp036</ArticleId>
            <ArticleId IdType="pmc">PMC2727208</ArticleId>
            <ArticleId IdType="pubmed">19318616</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Garcia-Becerra R, Santos N, Diaz L, Camacho J. Mechanisms of resistance to endocrine therapy in breast cancer: focus on signaling pathways, miRNAs and genetically based resistance. Int J Mol Sci. 2012;14:108–145. doi: 10.3390/ijms14010108.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/ijms14010108</ArticleId>
            <ArticleId IdType="pmc">PMC3565254</ArticleId>
            <ArticleId IdType="pubmed">23344024</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cardoso F, Senkus E, Costa A, et al.  4th ESO–ESMO international consensus guidelines for advanced breast cancer (ABC 4) Ann Oncol. 2018;29:1634–1657. doi: 10.1093/annonc/mdy192.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/annonc/mdy192</ArticleId>
            <ArticleId IdType="pmc">PMC7360146</ArticleId>
            <ArticleId IdType="pubmed">30032243</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer, version 1.2020.</Citation>
        </Reference>
        <Reference>
          <Citation>Im SA, Lu YS, Bardia A, et al.  Overall survival with ribociclib plus endocrine therapy in breast cancer. N Engl J Med. 2019;381:307–316. doi: 10.1056/NEJMoa1903765.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1903765</ArticleId>
            <ArticleId IdType="pubmed">31166679</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Slamon DJ, Neven P, Chia S, et al.  Overall survival (OS) results of the phase III MONALEESA-3 trial of postmenopausal patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor 2-negative (HER2−) advanced breast cancer (ABC) treated with fulvestrant (FUL) ± ribociclib (RIB) Ann Oncol. 2019;30:v851–v934. doi: 10.1093/annonc/mdz394.007.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/annonc/mdz394.007</ArticleId>
            <ArticleId IdType="pubmed">34102253</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hortobagyi GN, Stemmer SM, Burris HA, et al.  Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer. Ann Oncol. 2018;29:1541–1547. doi: 10.1093/annonc/mdy155.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/annonc/mdy155</ArticleId>
            <ArticleId IdType="pubmed">29718092</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Aapro MS, Kohne CH, Cohen HJ, Extermann M. Never too old? Age should not be a barrier to enrollment in cancer clinical trials. Oncologist. 2005;10:198–204. doi: 10.1634/theoncologist.10-3-198.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1634/theoncologist.10-3-198</ArticleId>
            <ArticleId IdType="pubmed">15793223</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lin NU, Amiri-Kordestani L, Palmieri D, Liewehr DJ, Steeg PS. CNS metastases in breast cancer: old challenge, new frontiers. Clin Cancer Res. 2013;19:6404–6418. doi: 10.1158/1078-0432.CCR-13-0790.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-13-0790</ArticleId>
            <ArticleId IdType="pmc">PMC7580496</ArticleId>
            <ArticleId IdType="pubmed">24298071</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Moelans CB, de Ligt J, van der Groep P, et al.  The molecular genetic make-up of male breast cancer. Endocr Relat Cancer. 2019;26:779–794. doi: 10.1530/ERC-19-0278.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1530/ERC-19-0278</ArticleId>
            <ArticleId IdType="pmc">PMC6938562</ArticleId>
            <ArticleId IdType="pubmed">31340200</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brufsky AM. Delaying chemotherapy in the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer. Clin Med Insights Oncol. 2015;9:137–147. doi: 10.4137/CMO.S31586.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4137/CMO.S31586</ArticleId>
            <ArticleId IdType="pmc">PMC4697769</ArticleId>
            <ArticleId IdType="pubmed">26793013</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Burton T, Byfield SD, Smith GL, et al.  Clinical and economic outcomes by first-line treatment among women with HR+/HER2- metastatic breast cancer in a large US health plan database. Curr Med Res Opin. 2016;32:1417–1423. doi: 10.1080/03007995.2016.1178108.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/03007995.2016.1178108</ArticleId>
            <ArticleId IdType="pubmed">27074160</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mitra D, Kurosky S, Zanotti G, Kaye J. Real-world treatment patterns and clinical outcomes in ER+/HER2- metastatic breast cancer: Results from a multicountry retrospective medical record review. Value Health. 2016 doi: 10.1016/j.jval.2016.03.1644.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jval.2016.03.1644</ArticleId>
            <ArticleId IdType="pubmed">29199086</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jacquet E, Lardy-Cleaud A, Pistilli B, et al.  Endocrine therapy or chemotherapy as first-line therapy in hormone receptor-positive HER2-negative metastatic breast cancer patients. Eur J Cancer. 2018;95:93–101. doi: 10.1016/j.ejca.2018.03.013.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ejca.2018.03.013</ArticleId>
            <ArticleId IdType="pubmed">29655061</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Novartis Europharm Limited. KISQALI (ribociclib) summary of product characteristics. https://www.ema.europa.eu/documents/product-information/kisqali-epar-product-information_en.pdf Accessed February 5, 2019.</Citation>
        </Reference>
        <Reference>
          <Citation>Eisenhauer EA, Therasse P, Bogaerts J, et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Eur J Cancer. 2009;45:228–47. doi: 10.1016/j.ejca.2008.10.026.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ejca.2008.10.026</ArticleId>
            <ArticleId IdType="pubmed">19097774</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brookmeyer R, Crowley J. A confidence interval for the median survival time. Biometrics. 1982;38:29–41. doi: 10.2307/2530286.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2307/2530286</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Clopper CJ, Pearson ES. The use of confidence or fiducial limits illustrated in the case of the binomial. Biometrika. 1934;26:404–413. doi: 10.1093/biomet/26.4.404.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/biomet/26.4.404</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eton DT, Cella D, Yost KJ, et al.  A combination of distribution- and anchor-based approaches determined minimally important differences (MIDs) for four endpoints in a breast cancer scale. J Clin Epidemiol. 2004;57:898–910. doi: 10.1016/j.jclinepi.2004.01.012.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jclinepi.2004.01.012</ArticleId>
            <ArticleId IdType="pubmed">15504633</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hortobagyi GN, Stemmer SM, Burris HA, et al.  Ribociclib as first-line therapy for HR-positive, advanced breast cancer. N Engl J Med. 2016;375:1738–1748. doi: 10.1056/NEJMoa1609709.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1609709</ArticleId>
            <ArticleId IdType="pubmed">27717303</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tripathy D, Im SA, Colleoni M, et al.  Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. Lancet Oncol. 2018;19:904–915. doi: 10.1016/S1470-2045(18)30292-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1470-2045(18)30292-4</ArticleId>
            <ArticleId IdType="pubmed">29804902</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rugo HS, Finn RS, Dieras V, et al.  Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up. Breast Cancer Res Treat. 2019;174:719–729. doi: 10.1007/s10549-018-05125-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10549-018-05125-4</ArticleId>
            <ArticleId IdType="pmc">PMC6438948</ArticleId>
            <ArticleId IdType="pubmed">30632023</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Goetz MP, Toi M, Campone M, et al.  MONARCH 3: Abemaciclib as initial therapy for advanced breast cancer. J Clin Oncol. 2017;35:3638–3646. doi: 10.1200/JCO.2017.75.6155.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2017.75.6155</ArticleId>
            <ArticleId IdType="pubmed">28968163</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Novartis Pharmaceuticals Corporation. KISQALI (ribociclib) prescribing information. https://www.pharma.us.novartis.com/sites/www.pharma.us.novartis.com/files/kisqali.pdf. Accessed February 5, 2019.</Citation>
        </Reference>
        <Reference>
          <Citation>Brady MJ, Cella DF, Mo F, et al.  Reliability and validity of the functional assessment of cancer therapy-breast quality-of-life instrument. J Clin Oncol. 1997;15:974–986. doi: 10.1200/JCO.1997.15.3.974.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.1997.15.3.974</ArticleId>
            <ArticleId IdType="pubmed">9060536</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rugo HS, Dieras V, Gelmon KA, et al.  Impact of palbociclib plus letrozole on patient-reported health-related quality of life: results from the PALOMA-2 trial. Ann Oncol. 2018;29:888–894. doi: 10.1093/annonc/mdy012.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/annonc/mdy012</ArticleId>
            <ArticleId IdType="pmc">PMC5913649</ArticleId>
            <ArticleId IdType="pubmed">29360932</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Verma S, O'Shaughnessy J, Burris HA, et al.  Health-related quality of life of postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer treated with ribociclib + letrozole: Results from MONALEESA-2. Breast Cancer Res Treat. 2018;170:535–545. doi: 10.1007/s10549-018-4769-z.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10549-018-4769-z</ArticleId>
            <ArticleId IdType="pmc">PMC6022531</ArticleId>
            <ArticleId IdType="pubmed">29654415</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Harbeck N, Franke F, Villanueva-Vazquez R, et al.  Health-related quality of life in premenopausal women with hormone-receptor-positive, HER2-negative advanced breast cancer treated with ribociclib plus endocrine therapy: Results from a phase III randomized clinical trial (MONALEESA-7) Ther Adv Med Oncol. 2020;12:1758835920943065. doi: 10.1177/1758835920943065.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/1758835920943065</ArticleId>
            <ArticleId IdType="pmc">PMC7385843</ArticleId>
            <ArticleId IdType="pubmed">32782490</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
